Do lentiviral vectors hold the answer to glaucoma therapy?

September 1, 2006

Fort Lauderdale, FL-Investigators have shown for the first time in nonhuman primates that, using lentiviral vectors, it is possible to achieve good gene marker expression that is sustained and that does not cause inflammation or other side effects. The most important factor in this research with lentiviral vectors is the longevity of the expression in contrast to adenoviral vectors, according to Eric Poeschla, MD.